

Ansgar W Lohse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6617648/publications.pdf>

Version: 2024-02-01

199
papers

12,241
citations

31976

53
h-index

29157

104
g-index

203
all docs

203
docs citations

203
times ranked

12021
citing authors

#	ARTICLE	IF	CITATIONS
1	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	7.3	1,553
2	Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. <i>Journal of Hepatology</i> , 2011, 54, 374-385.	3.7	470
3	Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 1198-1206.	1.3	394
4	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 1647-1660.	27.0	355
5	Immune tolerance: What is unique about the liver. <i>Journal of Autoimmunity</i> , 2010, 34, 1-6.	6.5	326
6	Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. <i>Lancet, The</i> , 2000, 355, 1510-1515.	13.7	318
7	Autoimmune hepatitis " Update 2015. <i>Journal of Hepatology</i> , 2015, 62, S100-S111.	3.7	290
8	Autoimmune hepatitis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18017.	30.5	280
9	Primary sclerosing cholangitis. <i>Lancet, The</i> , 2018, 391, 2547-2559.	13.7	276
10	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. <i>Gastroenterology</i> , 2014, 147, 443-452.e5.	1.3	268
11	Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatic form of PBC in genetically susceptible individuals. <i>Hepatology</i> , 1999, 29, 1078-1084.	7.3	259
12	Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. <i>Journal of Hepatology</i> , 2013, 58, 529-534.	3.7	202
13	Hepatitis E Seroprevalence in Europe: A Meta-Analysis. <i>Viruses</i> , 2016, 8, 211.	3.3	188
14	TGF- β 2-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. <i>Journal of Hepatology</i> , 2014, 61, 594-599.	3.7	185
15	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015, 15, 564.	2.6	182
16	Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?. <i>American Journal of Gastroenterology</i> , 2008, 103, 3063-3070.	0.4	179
17	Hepatitis E virus: Infection beyond the liver?. <i>Journal of Hepatology</i> , 2017, 66, 1082-1095.	3.7	174
18	Autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 171-182.	3.7	170

#	ARTICLE	IF	CITATIONS
19	Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. <i>Journal of Hepatology</i> , 2015, 62, 1349-1356.	3.7	145
20	Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. <i>Journal of Hepatology</i> , 1999, 31, 635-640.	3.7	142
21	Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 413-419.	0.4	137
22	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , 2016, 63, 1357-1367.	7.3	133
23	Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2013, 58, 1084-1093.	7.3	132
24	Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. <i>Journal of Hepatology</i> , 2016, 65, 769-775.	3.7	127
25	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. <i>Gut</i> , 2018, 67, 542-552.	12.1	125
26	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 827-838.	9.1	125
27	Clonal expansion and activation of tissue-resident memory-like T _H 17 cells expressing GM-CSF in the lungs of patients with severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	125
28	SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 162-172.e9.	4.4	113
29	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. <i>Cell Reports</i> , 2017, 20, 2251-2261.	6.4	107
30	Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. <i>Journal of Hepatology</i> , 2016, 64, 1033-1040.	3.7	106
31	Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. <i>Journal of Hepatology</i> , 2015, 63, 346-353.	3.7	104
32	Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series. <i>Annals of Internal Medicine</i> , 1999, 131, 943.	3.9	96
33	Molecular and functional heterogeneity of IL-10-producing CD4+ T cells. <i>Nature Communications</i> , 2018, 9, 5457.	12.8	93
34	Reduced FOXP3+ regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. <i>Journal of Hepatology</i> , 2014, 60, 1010-1016.	3.7	90
35	Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 754-763.	3.7	90
36	SARS-CoV-2 infection in patients with autoimmune hepatitis. <i>Journal of Hepatology</i> , 2021, 74, 1335-1343.	3.7	90

#	ARTICLE	IF	CITATIONS
37	Prospective Randomized Comparison of Minilaparoscopy and Percutaneous Liver Biopsy. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 103-110.	2.2	87
38	The Clinical Perspective on Hepatitis E. <i>Viruses</i> , 2019, 11, 617.	3.3	85
39	Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 445-453.	4.4	84
40	Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study. <i>Hepatology</i> , 2019, 69, 258-269.	7.3	83
41	Evaluation of F-Actin ELISA for the Diagnosis of Autoimmune Hepatitis. <i>American Journal of Gastroenterology</i> , 2006, 101, 2731-2736.	0.4	82
42	Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2015, 62, 642-646.	3.7	82
43	HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. <i>Journal of Hepatology</i> , 2018, 69, 36-42.	3.7	80
44	Alterations of the bile microbiome in primary sclerosing cholangitis. <i>Gut</i> , 2020, 69, 665-672.	12.1	80
45	Characteristics and Long-term Prognosis of the Autoimmune Hepatitis/Primary Sclerosing Cholangitis Overlap Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 75-80.	2.2	77
46	Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. <i>Journal of Hepatology</i> , 2014, 60, 538-544.	3.7	74
47	Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. <i>Liver International</i> , 2018, 38, 15-22.	3.9	71
48	Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. <i>Journal of Hepatology</i> , 2014, 60, 500-507.	3.7	68
49	Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1733-1738.	4.4	66
50	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. <i>Gut</i> , 2019, 68, 150-157.	12.1	65
51	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2022, 76, 841-849.	3.7	64
52	The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. <i>Journal of Hepatology</i> , 2019, 71, 465-472.	3.7	59
53	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. <i>Oncotarget</i> , 2017, 8, 89978-89987.	1.8	58
54	Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. <i>Hepatology</i> , 2002, 35, 403-408.	7.3	56

#	ARTICLE	IF	CITATIONS
55	Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. <i>Hepatology</i> , 2015, 62, 1456-1465.	7.3	56
56	Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. <i>Molecular Cancer Research</i> , 2018, 16, 496-507.	3.4	55
57	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2068-2075.e2.	4.4	55
58	Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2020, 73, 1496-1506.	3.7	55
59	A disease-specific decline of the relative abundance of <i>Bifidobacterium</i> in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1417-1428.	3.7	55
60	<i>Saccharomyces boulardii</i> to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw011.	0.9	54
61	Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 260-267.e1.	4.4	54
62	Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 329-336.	1.5	53
63	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020, 73, 453-455.	3.7	51
64	Testosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis. <i>Journal of Immunology</i> , 2015, 194, 2522-2530.	0.8	50
65	Monocytes as Potential Mediators of Pathogen-Induced T _H 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). <i>Hepatology</i> , 2020, 72, 1310-1326.	7.3	50
66	Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4 ⁺ T cells in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 414-423.	3.7	49
67	TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice. <i>Scientific Reports</i> , 2017, 7, 714.	3.3	48
68	Treatment response in patients with autoimmune hepatitis. <i>Hepatology</i> , 2010, 52, 2247-2248.	7.3	47
69	Characterization of the immune cell landscape of patients with NAFLD. <i>PLoS ONE</i> , 2020, 15, e0230307.	2.5	46
70	Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute <i>Plasmodium falciparum</i> Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1870.	4.8	45
71	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2016, 11, e0164224.	2.5	45
72	Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group. <i>Liver International</i> , 2022, 42, 1058-1069.	3.9	45

#	ARTICLE	IF	CITATIONS
73	Hepatitis E seroprevalence in the Americas: A systematic review and meta-analysis. <i>Liver International</i> , 2018, 38, 1951-1964.	3.9	44
74	Association of autoimmune hepatitis and systemic lupus erythematosus: A case series and review of the literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 12662.	3.3	42
75	Disturbed lipid and amino acid metabolisms in COVID-19 patients. <i>Journal of Molecular Medicine</i> , 2022, 100, 555-568.	3.9	42
76	Defective T Helper Response of Hepatocyte-Stimulated CD4 T Cells Impairs Antiviral CD8 Response and Viral Clearance. <i>Gastroenterology</i> , 2007, 133, 2010-2018.	1.3	39
77	Acute Ebola virus disease patient treatment and health-related quality of life in health care professionals: A controlled study. <i>Journal of Psychosomatic Research</i> , 2016, 83, 69-74.	2.6	39
78	Autoimmune(-Like) Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1954.	4.1	39
79	Comprehensive characterization of cellular immune responses following Ebola virus infection. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw508.	4.0	38
80	A Protective Function of IL-22BP in Ischemia Reperfusion and Acetaminophen-Induced Liver Injury. <i>Journal of Immunology</i> , 2017, 199, 4078-4090.	0.8	38
81	Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 232, 113671.	4.3	37
82	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 951-960.	3.7	34
83	Long-term outcome in PSC/AIH overlap syndrome: Does immunosuppression also treat the PSC component?. <i>Journal of Hepatology</i> , 2014, 61, 1189-1191.	3.7	33
84	Persistent SOMATIC symptoms ACROSS diseases – from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). <i>BMJ Open</i> , 2022, 12, e057596.	1.9	33
85	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. <i>Gastroenterology</i> , 2020, 159, 1417-1430.e3.	1.3	31
86	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. <i>Journal of Hepatology</i> , 2021, 74, 312-320.	3.7	31
87	The Development of Irritable Bowel Syndrome: A Prospective Community-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 1320-1329.	0.4	30
88	Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. <i>JHEP Reports</i> , 2019, 1, 90-98.	4.9	30
89	Detectable Vesicular Stomatitis Virus (VSV) Specific Humoral and Cellular Immune Responses Following VSV Ebola Virus Vaccination in Humans. <i>Journal of Infectious Diseases</i> , 2019, 219, 556-561.	4.0	29
90	CD4+ T-Cell Help Is Required for Effective CD8+ T Cell-Mediated Resolution of Acute Viral Hepatitis in Mice. <i>PLoS ONE</i> , 2014, 9, e86348.	2.5	28

#	ARTICLE	IF	CITATIONS
91	HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules. <i>Scientific Reports</i> , 2019, 9, 10624.	3.3	27
92	Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, 941-953.	3.7	27
93	SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies. <i>Viruses</i> , 2021, 13, 661.	3.3	27
94	SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. <i>United European Gastroenterology Journal</i> , 2022, 10, 319-329.	3.8	27
95	Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling. <i>Journal of Hepatology</i> , 2017, 66, 798-805.	3.7	26
96	Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 783-792.	3.7	26
97	Psychological Outcome, Fatigue, and Quality of Life After Infection With Shiga Toxin-Producing <i>Escherichia coli</i> O104. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1848-1855.	4.4	25
98	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1609-1617.e4.	4.4	25
99	Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. <i>Liver Transplantation</i> , 2020, 26, 866-877.	2.4	25
100	Next-Generation Immunosequencing Reveals Pathological T-Cell Architecture in Autoimmune Hepatitis. <i>Hepatology</i> , 2021, 73, 1436-1448.	7.3	25
101	Reduced CD161+ MAIT cell frequencies in HCV and HIV/HCV co-infection: Is the liver the heart of the matter?. <i>Journal of Hepatology</i> , 2016, 65, 1261-1263.	3.7	24
102	High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. <i>BMC Cancer</i> , 2017, 17, 60.	2.6	24
103	Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors. <i>Journal of Clinical Virology</i> , 2018, 105, 26-30.	3.1	23
104	Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. <i>Cancers</i> , 2021, 13, 2484.	3.7	23
105	Diagnostic criteria for autoimmune hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 665-671.	2.4	22
106	Transient Elastography in Primary Sclerosing Cholangitis—the Value as a Prognostic Factor and Limitations. <i>Gastroenterology</i> , 2014, 147, 542-543.	1.3	21
107	Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice. <i>Hepatology</i> , 2016, 64, 508-521.	7.3	21
108	Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. <i>Liver International</i> , 2020, 40, 368-376.	3.9	21

#	ARTICLE	IF	CITATIONS
109	Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. <i>International Journal of Obesity</i> , 2021, 45, 2197-2204.	3.4	21
110	Acute autoimmune hepatitis: Many open questions. <i>Journal of Hepatology</i> , 2014, 61, 727-729.	3.7	20
111	Disease Duration and Stage Influence Bone Microstructure in Patients With Primary Biliary Cholangitis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1011-1019.	2.8	20
112	Autoimmune hepatitis on the rise. <i>Journal of Hepatology</i> , 2014, 60, 478-479.	3.7	19
113	Liver transplantation for acute-to-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. <i>Liver International</i> , 2021, 41, 574-584.	3.9	19
114	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. <i>Journal of Clinical Medicine</i> , 2021, 10, 2274.	2.4	19
115	Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin. <i>PLoS ONE</i> , 2014, 9, e96533.	2.5	17
116	Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management. <i>Digestive Diseases</i> , 2016, 34, 334-339.	1.9	17
117	Hepatitis E virus persists in the ejaculate of chronically infected men. <i>Journal of Hepatology</i> , 2021, 75, 55-63.	3.7	17
118	Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 431-438.	0.5	17
119	TLR7-mediated activation of XBP1 correlates with the IFN γ production in humans. <i>Cytokine</i> , 2017, 94, 55-58.	3.2	16
120	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, <i>Pneumocystis jirovecii</i> -pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). <i>AIDS Research and Therapy</i> , 2019, 16, 34.	1.7	16
121	Chronic Hepatitis E is associated with cholangitis. <i>Liver International</i> , 2019, 39, 1876-1883.	3.9	16
122	Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. <i>Frontiers in Immunology</i> , 2019, 10, 1065.	4.8	16
123	Treatment and re-treatment results of HCV patients in the DAA era. <i>PLoS ONE</i> , 2020, 15, e0232773.	2.5	16
124	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020, 40, 2164-2171.	3.9	16
125	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	7.3	16
126	Factors associated with long-term survival after liver transplantation: A retrospective cohort study. <i>World Journal of Hepatology</i> , 2017, 9, 427.	2.0	16

#	ARTICLE	IF	CITATIONS
127	No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1806-1812.	4.4	15
128	CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood. <i>Journal of Leukocyte Biology</i> , 2017, 101, 589-597.	3.3	15
129	A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 226-233.e3.	4.4	15
130	Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure. <i>World Journal of Gastroenterology</i> , 2015, 21, 2214-2219.	3.3	14
131	Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2022, 22, 626-633.	4.7	14
132	Variant syndromes of primary biliary cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 55-61.	2.4	13
133	Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 238, 113851.	4.3	13
134	Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma—correlation with liver cancer and liver cirrhosis. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 7965-7977.	3.7	12
135	No link between male infertility and HEV genotype 3 infection. <i>Gut</i> , 2020, 69, 1150-1151.	12.1	12
136	Review article: experimental therapies in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1134-1149.	3.7	12
137	Autoimmune hepatitis: Possible triggers, potential treatments. <i>Journal of Hepatology</i> , 2020, 73, 446-448.	3.7	12
138	Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. <i>United European Gastroenterology Journal</i> , 2021, 9, 797-808.	3.8	12
139	B cells in autoimmune hepatitis: bystanders or central players?. <i>Seminars in Immunopathology</i> , 2022, 44, 411-427.	6.1	12
140	Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. <i>PLoS ONE</i> , 2018, 13, e0190005.	2.5	11
141	Clinical and Radiological Characterization of Patients with Immobilizing and Progressive Stress Fractures in Methotrexate Osteopathy. <i>Calcified Tissue International</i> , 2021, 108, 219-230.	3.1	11
142	Aryl Hydrocarbon Receptor Activity in Hepatocytes Sensitizes to Hyperacute Acetaminophen-Induced Hepatotoxicity in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 371-388.	4.5	11
143	Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A. <i>Pathogens</i> , 2021, 10, 60.	2.8	11
144	Role of mycophenolate mofetil in the treatment of autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 510-511.	3.7	10

#	ARTICLE	IF	CITATIONS
145	High Clinical Manifestation Rate in an Imported Outbreak of Hepatitis E Genotype 1 Infection in a German Group of Travellers Returning from India. <i>Annals of Hepatology</i> , 2017, 16, 57-62.	1.5	10
146	Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1043-1056.	4.2	10
147	Nonalcoholic Fatty Liver Disease in Patients with Autoimmune Hepatitis: Further Reason for Teeth GNASHing?. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2462-2464.	2.3	9
148	Transjugular Intrahepatic Portosystemic Shunt (TIPS) for primary and secondary prophylaxis of variceal bleeding in hepatic schistosomiasis. <i>Travel Medicine and Infectious Disease</i> , 2019, 30, 130-132.	3.0	9
149	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2015, 10, e0140525.	2.5	8
150	Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis. <i>Pediatrics</i> , 2016, 138, .	2.1	8
151	Haem oxygenase-1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice. <i>Liver International</i> , 2017, 37, 1128-1137.	3.9	8
152	Epidemiology, clinical and laboratory features of 24 consecutive cases of leptospirosis at a German infectious disease center. <i>Infection</i> , 2018, 46, 847-853.	4.7	8
153	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1391-1396.	1.5	8
154	Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors. <i>Endocrine</i> , 2019, 65, 460-467.	2.3	7
155	Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection. <i>Pathogens</i> , 2020, 9, 755.	2.8	7
156	Risk factors for different intestinal pathogens among patients with traveler's diarrhea: A retrospective analysis at a German travel clinic (2009-2017). <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101706.	3.0	6
157	Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas. <i>PLoS ONE</i> , 2020, 15, e0231833.	2.5	6
158	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	1.3	6
159	Cardiovascular magnetic resonance demonstrates structural cardiac changes following transjugular intrahepatic portosystemic shunt. <i>Scientific Reports</i> , 2021, 11, 12719.	3.3	6
160	Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 86-90.	2.3	6
161	Rolls Royce for everybody? Diagnosing liver disease by mini-laparoscopy. <i>Journal of Hepatology</i> , 2011, 54, 584-585.	3.7	5
162	Risk factors for excessively prolonged meropenem use in the intensive care setting: a case-control study. <i>BMC Infectious Diseases</i> , 2017, 17, 131.	2.9	5

#	ARTICLE	IF	CITATIONS
163	Endoscopic retrograde cholangiography and percutaneous transhepatic cholangiodrainage in biliary strictures after liver transplantation: Long-term outcome predictors and influence on patient survival. <i>Liver International</i> , 2019, 39, 1155-1164.	3.9	5
164	Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial. <i>Trials</i> , 2022, 23, 302.	1.6	5
165	Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1532-1544.	3.7	5
166	Can Understanding the Pathogenesis of Autoimmune Hepatitis Lead to Rational Therapy?. <i>Digestive Diseases</i> , 2017, 35, 367-370.	1.9	4
167	Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or survival. <i>Annals of Hepatology</i> , 2021, 26, 100559.	1.5	4
168	Diagnosis of abdominal tuberculosis by mini-laparoscopy. <i>Infection</i> , 2022, 50, 1049-1050.	4.7	4
169	Predictors of somatic symptom burden in healthcare professionals during the COVID-19 pandemic: an 8-week follow-up study. <i>Journal of Mental Health</i> , 2023, 32, 1111-1121.	1.9	4
170	Diffusion-weighted MRI for detection of hepatic osteodystrophy in primary sclerosing cholangitis: a comparison study with dual-energy X-ray absorptiometry. <i>Japanese Journal of Radiology</i> , 2016, 34, 677-683.	2.4	3
171	Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation. <i>Pancreatology</i> , 2017, 17, 898-904.	1.1	3
172	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. <i>Journal of Hepatology</i> , 2020, 73, 1285-1287.	3.7	3
173	Bone microarchitecture in patients with autoimmune hepatitis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1316-1325.	2.8	3
174	Leukocyte-Derived High-Mobility Group Box 1 Governs Hepatic Immune Responses to <i>Listeria monocytogenes</i> . <i>Hepatology Communications</i> , 2021, 5, 2104-2120.	4.3	3
175	Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. <i>Oncotarget</i> , 2016, 7, 55639-55648.	1.8	3
176	Reply to: "Anti-TNF-induced autoimmune hepatitis". <i>Journal of Hepatology</i> , 2014, 61, 170-171.	3.7	2
177	Time trend of reported cases and publications: hepatitis E in comparison to hepatitis A in Germany from 2001 to 2016. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 29-35.	0.5	2
178	Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis". <i>Journal of Hepatology</i> , 2021, 74, 755-756.	3.7	2
179	Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 840-848.	1.5	2
180	Response for letter "Be cautious in comparing the seroprevalence of hepatitis E detected at different years in different countries". <i>Liver International</i> , 2018, 38, 2341-2341.	3.9	1

#	ARTICLE	IF	CITATIONS
181	Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature. <i>GastroHep</i> , 2019, 1, 33-44.	0.6	1
182	Autoimmune hepatitis: Is the autoimmunity in the family?. <i>Liver International</i> , 2019, 39, 42-44.	3.9	1
183	Autoantibodies to intracellular "rods and rings" structures in two patients with autoimmune hepatitis treated with azathioprine. <i>Autoimmunity</i> , 2020, 53, 362-365.	2.6	1
184	Prevalence and risk factors of undiagnosed diabetes mellitus among gastroenterological patients: a HbA1c-based single center experience " Prevalence of undiagnosed diabetes in gastroenterological patients. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1306-1313.	0.5	1
185	FXR antagonists as new agents for COVID19. , 2021, , .		1
186	Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101760.	1.5	1
187	Low incidence of colonic complications after severe Shiga toxin-producing E. coli O104:H4 infection. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1104-1110.	0.5	1
188	Advances in genetic, epigenetic and environmental aspects of rare liver diseases. <i>European Journal of Medical Genetics</i> , 2022, 65, 104411.	1.3	1
189	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment. <i>Cancers</i> , 2022, 14, 768.	3.7	1
190	Reply:. <i>Hepatology</i> , 2009, 49, 1783-1783.	7.3	0
191	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1063-1064.	4.4	0
192	Autoimmune Hepatitis: When Is It Safe to Stop Therapy, or Withhold Therapy Altogether?. <i>Current Hepatology Reports</i> , 2017, 16, 113-118.	0.9	0
193	Bilateral Hematothorax Without Hematemesis" An Unusual Presentation of Variceal Bleeding. <i>Hepatology</i> , 2021, 73, 1233-1235.	7.3	0
194	Low antibody titers after second SARS-CoV-2 vaccination in patients with autoimmune hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
195	Title is missing!. , 2020, 15, e0231833.		0
196	Title is missing!. , 2020, 15, e0231833.		0
197	Title is missing!. , 2020, 15, e0231833.		0
198	Title is missing!. , 2020, 15, e0231833.		0

#	ARTICLE	IF	CITATIONS
199	Histological spectrum of autoimmune hepatitisâ€™”reply to Fujiwara K. et al.. Liver International, 2022, 42, 1704-1705.	3.9	0